Danaher posted FY revenue of $24.6B, up just 2.9% YoY, a pace that has fallen short of the more robust recovery many investors anticipated after the post-COVID bioprocessing destocking cycle. Gross margins remain healthy at 59.1%, but net margins of 14.7% and diluted EPS of $5.05 reflect a business still grinding through normalization rather than inflecting higher.

The key question is whether the modest revenue ramp signals a durable bottom or a prolonged plateau in the life sciences tools cycle. Investors will be watching order trends in bioprocessing, any commentary on Biotek segment recovery, and whether peer indicators from companies like Sartorius or Cytiva reinforce or contradict DHR's trajectory as the next earnings cycle approaches.